Phase 2 N=49 Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Lymphoma
Primary: Number of Participants With Time to Progression (TTP) — 42; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Phase 2 N=87 S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Lymphoma
Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants
Phase 2 N=28 Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
Lymphoma
Primary: Progression-free Survival at 1 Year — 38 percentage of participants
Phase 2 N=90 Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
Ann Arbor Stage II Grade 1 Follicular Lymphoma · Ann Arbor Stage II Grade 2 Follicular Lymphoma · Ann Arbor Stage III Grade 1 Follicular Lymphoma
Primary: Progression Free Survival — 70.7 months
Phase 2 N=24 Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Refractory Follicular Lymphoma · Relapsed Follicular Lymphoma
Primary: Recommended Phase 2 Dose (RP2D) — 0; 1; 0; 0 Dose Limiting toxicities
N/A N=41 A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma
Lymphoma, Follicular
Primary: Percentage of Participants With Objective Response — 92.3 percentage of participants
N/A N=260 Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)
Follicular Lymphoma
Primary: Percentage of Participants With Modalities of the Therapeutic Decision Before First Study Induction Treatment Phase — 81.9; 8.4; 6.3; 3.4 percentage of participants
Phase 2 N=51 Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Lymphoma
Primary: Overall Response Rate (Complete or Partial Response) by Month 12 — 60; 84 percentage of patients
Phase 2 N=39 Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Lymphoma, Follicular
Primary: Number of Participants With Complete Response at 3 Years — 30 Participants
Phase 2 N=96 Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Non-Hodgkin's Lymphoma
Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients
Phase 2 N=56 Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
Follicular Lymphoma · Non-Hodgkin's Lymphoma Follicular · Non-Hodgkin's Lymphoma, Adult High Grade
Primary: Complete Response (CR) at End of Induction — 41; 11; 1; 0 Participants
Phase 2 N=289 Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Lymphoma
Primary: Complete Remission (CR) Rate — 0.62; 0.75 proportion of participants — p=0.02
Phase 2 N=65 Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
Primary: Number of Participants Who Achieved a Complete Response — 47 Participants
Phase 2 N=64 Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma
Follicular Lymphoma
Primary: Progression-free Survival — 59 percent chance of PFS at 5 years
Phase 2 N=59 Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients
Lymphoma, Follicular
Primary: Number of Participants With the Indicated Overall Best Response (OBR) at Visit 26 (3 Months After the Last Infusion of Ofatumumab) — 6; 9; 10; 7 participants
Phase 2 N=16 Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
Follicular Lymphoma
Primary: Number of Participants With Overall Response Rate (ORR) — 0; 0; 0; 0 participants
Phase 4 N=113 An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
Advanced Follicular Lymphoma
Primary: Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle…
Phase 3 N=358 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Lymphoma, Non-Hodgkin
Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…
Phase 2 N=28 Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants
Phase 2 N=55 Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
Relapsed Follicular Lymphoma
Primary: Number of Patients With Complete Response (CR) — 1; 13 participants
Phase 2 N=138 Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Lymphoma
Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants
Phase 2 N=21 TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma · Grade 3a Follicular Lymphoma
Primary: Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) — 1; 0 Participants
Phase 2 N=67 Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
Lymphoma
Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants
Phase 3 N=1,030 Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Follicular Lymphoma
Primary: Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review — 48.1; 53.0 Percent of participants — p=0.128
Phase 2 N=52 Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma
Lymphoma
Primary: Complete Response Rate — 23 percentage of participants
Phase 2 N=60 R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Non-Hodgkin's Lymphoma
Primary: Response Rate — 57; 35 Participants
Phase 2 N=348 Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL) · Primary Mediastinal Large B-cell Lymphoma · Burkitt Lymphoma
Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants
Phase 2 N=116 HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab
Lymphoma, Follicular
Primary: Number of Participants With Objective Response (OR) — 0; 1; 2; 0 participants
Phase 3 N=124 A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
Lymphoma, Follicular
Primary: Event-free Survival — 53.944 months